Figure 6.

Combined treatment with ABT263 and G-TPP prolongs survival in glioma models in vivo. A, 3×10⁵ GBM12 cells were implanted into the right striatum of nude mice. Once tumors formed animals were randomized and treated subcutaneously 3×/week with vehicle (n=5), ABT263 25mg/kg (n=6), G-TPP 5mg/kg (n=5) or the combination (n=5). Kaplan-Meier plots were calculated for analysis of survival. Animals treated with ABT263+Gamitrinib-TPP had a significantly longer overall survival than animals receiving, vehicle, ABT263 or Gamitrinib-TPP (p<0.05, log-rank (Mantel-Cox) test). B, Representative MRI images of animals treated as described for A towards the end of the experiment. C=vehicle, A=ABT263, G=G-TPP, AG=ABT263 plus G-TPP. C–F, 1×10⁶ LN229 (C–D) and U251 (E–F) glioblastoma cells were implanted subcutaneously. After tumor formation animals were treated intraperitoneally with vehicle, G-TPP (5 mg/kg), ABT263 (50 mg/kg) or both agents. Data are presented as mean and SEM. Tumor growth curves show the development of tumor size for each treatment group. Scatter plots display the quantitative representation of the tumor size among the different treatments toward the end of the experiments. A Photograph of representative tumors is shown for U251 (F). G–H, 1×10⁶ U87MG glioblastoma cells were implanted subcutaneously. After tumor formation animals were treated intraperitoneally with vehicle, G-TPP (5 mg/kg), GX15-070 (5 mg/kg) or both agents. Data are presented as mean and SEM. Tumor growth curves show the development of tumor size for each treatment group (G). Scatter plots display the quantitative representation of the tumor size among the different treatments toward the end of the experiments (H).